Liquid Biopsy in Gastrointestinal Cancers: How Close Are We to Reaching the Clinic?
Open Access
Abstract
Gastrointestinal (GI) cancers are malignancies that develop within the digestive system and account for one in four cancer cases according to WHO dataKeywords
Funding Information
- European Union’s Horizon 2020 Research and Innovation Program (857381/VISION, CB16/12/00446, APVV-21-0197, APVV-20-0143)
- Spanish Biomedical Research Network in Cancer CIBERONC (857381/VISION, CB16/12/00446, APVV-21-0197, APVV-20-0143)
- Slovak Research and Development Agency (857381/VISION, CB16/12/00446, APVV-21-0197, APVV-20-0143)
- TRANSCAN-2 program ERA-NET JTC 2017 (857381/VISION, CB16/12/00446, APVV-21-0197, APVV-20-0143)
This publication has 24 references indexed in Scilit:
- Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2020
- Plasma or Serum: Which Is Preferable for Mutation Detection in Liquid Biopsy?Clinical Chemistry, 2020
- Global Burden of 5 Major Types of Gastrointestinal CancerGastroenterology, 2020
- Global burden of cancer attributable to infections in 2018: a worldwide incidence analysisThe Lancet Global Health, 2020
- Targeting minimal residual disease: a path to cure?Nature Reviews Cancer, 2018
- Recommendations on Fecal Immunochemical Testing to Screen for Colorectal Neoplasia: A Consensus Statement by the US Multi-Society Task Force on Colorectal CancerGastroenterology, 2017
- The effectiveness of FOBT vs. FIT: A meta-analysis on colorectal cancer screening test2016
- Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid BiopsyCancer Discovery, 2016
- Circulating tumour cells in cancer patients: challenges and perspectivesTrends in Molecular Medicine, 2010
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009